No Data
No Data
Sino Biopharm Trustee Purchases 15.8 Million Shares Under Incentive Scheme
The trustee of Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing purchased 15.8 million shares between June 5 and June 13 under a share award scheme, according to a Thursday filing with the Hon
Sino Biopharm (01177.HK): SDIC Tianqing Pharmaceutical Co., Ltd. Incentive Plan Buys Shares
Sino Biopharm (01177.HK) announced that on May 7, 2024, China Biopharmaceuticals Co., Ltd. made an announcement on the implementation of equity incentive plan for its subsidiary, Zhejiang Jingxin Tianqing Pharmaceutical Group Co., Ltd. ("Jingxin Tianqing"). From June 5, 2024 to June 13, 2024, the trustee purchased a total of 15.842 million shares of the company on the market according to the terms and conditions of the share incentive plan, which will be used for subsequent implementation of share incentives for selected participants.
Sino Biopharmaceutical (01177) rose more than 3% in Hong Kong Stocks. Its contrast agent, "Gadolinium Ethanol Injection", was approved for listing by the National Medical Products Administration.
Sino Biopharm (01177) rose by over 3%. As of press time, it has risen by 3.28% to HK $2.83, with a turnover of HK $70.589 million.
Sino Biopharm (01177): "Gadoteric Acid Injection" has been approved for marketing.
Sino Biopharm (01177) announced that the group's medical imaging product "Gadoteric acid injection"...
Express News | Sino Biopharmaceutical - Approval for Marketing of Gadoteridol Injection From Nmpa
Sino Biopharmaceutical Limited Goes Ex Dividend Tomorrow
No Data